Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan for Post-Transplant Recurrent C3G or IC-MPGN
2024-511544-36-00Phase 2Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Nov 2024
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial in Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) comparing Pegcetacoplan (ASPAVELI) with Control (standard of care) (2 arms). Started Nov 2024; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on 2024-511544-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511544-36-00.